Australia has one of the highest prevalence rates for asthma in the world, affecting around 15% of the population. Short-acting beta2 agonists (SABAs) have a longstanding role as the main treatment option for the acute relief of symptoms, while more recently long-acting beta2 agonists (LABAs) have been recommended for use as add-on therapy to inhaled corticosteroids for the prevention of symptoms.
History
Publication title
Australian Pharmacist
Volume
32
Issue
5
Pagination
54-57
ISSN
0728-4632
Department/School
School of Pharmacy and Pharmacology
Publisher
Pharmaceutical Society of Australia
Place of publication
Deakin West, ACT.
Rights statement
Copyright 2013 Pharmaceutical Society of Australia Ltd